Article
6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial.
Clinical chemistry - 1 Jul 2007
Reinshagen Max, Schütz Ekkehard, Armstrong Victor W, Behrens Christoph, von Tirpitz Christian, Stallmach Andreas, Herfarth Hans, Stein Jürgen, Bias Peter, Adler Guido, Shipkova Maria, Kruis Wolfgang, Oellerich Michael, von Ahsen Nicolas
Abstract excerpt
BACKGROUND: A prospective randomized trial in patients with Crohn disease studied whether 6-thioguanine nucleotide (6-TGN) concentration-adapted azathioprine (AZA) therapy is clinically superior to a standard dose of 2.5 mg/kg/day AZA. METHODS: After 2 weeks of standard therapy, patients (n = 71)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.